GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Price-to-Operating-Cash-Flow

Statera BioPharma (Statera BioPharma) Price-to-Operating-Cash-Flow : (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Price-to-Operating-Cash-Flow?

As of today (2024-04-27), Statera BioPharma's share price is $0.0007. Statera BioPharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.32. Hence, Statera BioPharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Statera BioPharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

STAB's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Statera BioPharma's Cash Flow from Operations per share for the three months ended in Sep. 2022 was $-0.02. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.32.


Statera BioPharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Statera BioPharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Price-to-Operating-Cash-Flow Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Price-to-Operating-Cash-Flow
- - -

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Statera BioPharma's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Statera BioPharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Price-to-Operating-Cash-Flow falls into.



Statera BioPharma Price-to-Operating-Cash-Flow Calculation

Statera BioPharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.0007/-0.324
=

Statera BioPharma's Share Price of today is $0.0007.
Statera BioPharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Statera BioPharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (Statera BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Executives
Satishchandran Chandrasekhar director 167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka director, officer: Chief Operating Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit officer: Chief Technology Officer C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M. officer: Chief Legal Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky officer: Chief Medical Officer 2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam officer: Chief Financial Officer 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick director TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203

Statera BioPharma (Statera BioPharma) Headlines

From GuruFocus

Statera Biopharma, Inc. Files Form 12b-25

By GuruFocusNews GuruFocusNews 03-31-2022